Added to YB: 2026-05-26
Pitch date: 2026-05-22
QTTB [bullish]
Q32 Bio Inc.
Author Info
No bio for this author
Company Info
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Market Cap
$98.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
2.61
P/E
2.24
EV/Sales
1.14
Sector
Biotechnology
Category
turnaround
A breakthrough biologic for hair loss trading at cash? - $QTTB
QTTB: Anti-IL-7Rα antibody Bempikibart Phase 2b AA topline results summer 2026. Trading at cash after 90% crash from failed AD trial Dec 2024. Phase 2a AA data showed activity. Thesis: modified protocol should match/exceed low-dose Baricitinib (SALT Δ14.2 @24wk). JAKi benchmark is 2mg dose (64% real-world usage) due to dose-dependent side effects. Potential for disease-modifying therapy vs JAKi suppression (80% relapse off-drug). High-risk binary bet on whether Phase 2a data can be trusted.
Read full article (5 min)